rs202161423
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP5BA1
This summary comes from the ClinGen Evidence Repository: The allele frequency of The p.Lys679Thr variant in UBE3A (NM_130838.2) is 0.03187% in European (non-Finnish) sub population in gnomAD v4, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Lys679Thr variant is found in a patient with an alternate molecular basis of disease (internal database - Baylor) (BP5). In summary, the p.Lys679Thr variant in UBE3A (NM_130838.2) is classified as benign based on the ACMG/AMP criteria (BA1, BP5). LINK:https://erepo.genome.network/evrepo/ui/classification/CA206151/MONDO:0007113/037
Frequency
Consequence
NM_130839.5 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -9 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152198Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000995 AC: 25AN: 251142 AF XY: 0.0000958 show subpopulations
GnomAD4 exome AF: 0.000257 AC: 375AN: 1461150Hom.: 0 Cov.: 31 AF XY: 0.000255 AC XY: 185AN XY: 726896 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152198Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74334 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Angelman syndrome Uncertain:2Benign:1
This sequence change replaces lysine, which is basic and polar, with threonine, which is neutral and polar, at codon 679 of the UBE3A protein (p.Lys679Thr). This variant is present in population databases (rs202161423, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with UBE3A-related conditions. ClinVar contains an entry for this variant (Variation ID: 156144). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt UBE3A protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
possible diagnosis of Angelman syndrome -
The allele frequency of The p.Lys679Thr variant in UBE3A (NM_130838.2) is 0.03187% in European (non-Finnish) sub population in gnomAD v4, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Lys679Thr variant is found in a patient with an alternate molecular basis of disease (internal database - Baylor) (BP5). In summary, the p.Lys679Thr variant in UBE3A (NM_130838.2) is classified as benign based on the ACMG/AMP criteria (BA1, BP5). -
not provided Uncertain:1Benign:1
This variant is associated with the following publications: (PMID: 25212744) -
- -
not specified Uncertain:1
- -
UBE3A-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at